Iran Press/America: Historically other vaccines, such as those for polio, started as injections but oral vaccines were developed, according to healthline.com.
More research is needed to find out if these oral or nasal spray vaccines will be as effective as injectable vaccines.
The three COVID-19 vaccines authorized in the United States may be key to helping get the pandemic under control in the near future.
But while these vaccines, released by Pfizer-BioNTech, Johnson & Johnson, and Moderna, are effective, they do come with some challenges.
All require getting an injection, which can make people with needle phobias extremely hesitant to get the shot. Additionally, side effects including feelings of fever, flu-like symptoms, and arm soreness are common with all three vaccines.
The Johnson & Johnson vaccine has been paused as officials investigate extremely rare blood clots that may be associated with the vaccine.
To make the vaccination process simpler and faster, researchers are working to develop the next generation of COVID-19 vaccines, namely in pill and nasal spray forms.
These next-generation vaccines may make it easier to eradicate the coronavirus from the globe.
How the original COVID-19 vaccines work
According to the Centers for Disease Control and Prevention (CDC), the current COVID-19 vaccines help our bodies develop immunity by supplying them with “memory” T-lymphocytes and B-lymphocytes. These white blood cells remember how to fight the coronavirus, should it enter your body in the future.
Currently, three types of COVID-19 vaccines are authorized in the United States, although the Johnson & Johnson vaccine has been temporarily paused as it potentially triggered a rare blood clot in a very small percentage of the population.
One vaccine is the mRNA vaccine. It contains material from the virus, which instructs our cells to make a protein unique to the coronavirus to fight it in the future.
Another vaccine is the protein subunit vaccine. It includes harmless proteins of the virus instead of the entire germ. After vaccination, the body recognizes the protein and will remember how to fight it.
The third type is the vector vaccine. It contains a modified version of a different virus. Inside the shell of the modified virus is material from the coronavirus. Once the viral vector is in the cell, the cells produce a protein and then copy it, which prompts our bodies to build the T- and B-lymphocytes that can protect against the coronavirus.
How a nasal spray or pill could protect you from COVID-19
ImmunityBio, one of the companies working to develop other versions of the COVID-19 vaccine including a capsule and a dissolvable tablet, has been authorized by the FDA to expand a phase 1 clinical trial.
The three injectable vaccines (Pfizer-BioNTech, Moderna, and Johnson & Johnson) prompt the immune response to generate antibodies that fight against the coronavirus spike protein.
The ImmunityBio vaccine, however, targets both the mutation-prone outer spike protein and the more stable inner protein, which activates antibodies, memory B cells, and T cells against the coronavirus.
The goal is to create longer-term protection as well as provide protection from variants.
Altimmune is another company working on a next-generation vaccine. This one would be a nasal spray.
A nasal delivery method is designed to produce an immune response at the point where the virus enters the body, causing mucosal immunity in the nasal cavity.
Called AdCOVID, the nasal spray vaccine is designed to stimulate an immune response including both antibody and T-cell responses in the nasal cavity.
What will the next generation of vaccines mean for the future of COVID-19?
At this point, it’s too early to know whether these vaccines will be as effective as the first round of injectable vaccines.
But past cases have shown that an original injectable vaccine can be followed by oral versions.
In 1953 the polio vaccine was introduced as an injectable. Nine years later an oral version was developed, which essentially wiped the poliovirus from the planet.
“We’re right on the edge of eliminating [polio] from the world. We’re doing something similar with an oral vaccine against rotavirus. We had a nasal flu vaccine, although that had its ups and downs,” Schaffner said. “It’s not a straight line here, but there are precedents.”
New vaccines that are easier to administer and target virus variants can only mean there’s potential for eradication of the coronavirus, or at least an easier way to prevent infection or lessen its effects.
“If you could deliver vaccines by an effective nasal spray or a pill, you could deliver vaccines safely to a huge number of people very quickly. You won’t need to have trained people to give injections. All issues of using needles and syringes safely would disappear,” Schaffner said.
Being able to store the vaccine at room temperature would also make it much easier to administer.
214/224
Read More:
Guterres: 2021 priority should be global vaccination
Iran producing COVID vaccine in 6 different ways: FDA head
27,000 people volunteer for Iranian COVID vaccine
